eMedicine Specialties > Emergency Medicine > Cardiovascular

Use of Cardiac Markers in the Emergency Department: Multimedia

Author: Donald Schreiber, MD, CM, Associate Professor of Surgery (Emergency Medicine), Stanford University School of Medicine
Coauthor(s): Suzanne M Miller, MD, Clinical Instructor, Emergency Medicine, George Washington University School of Medicine and Health Sciences; Attending Physician, Department of Emergency Medicine, INOVA Fairfax Hospital; Chief Executive Officer, MDadmit
Contributor Information and Disclosures

Updated: Jul 8, 2009

Multimedia

Use of cardiac markers in the ED. Studies on trop...
(Enlarge Image)
Media file 1: Use of cardiac markers in the ED. Studies on troponins in acute coronary syndrome.
[ CLOSE WINDOW ]
Use of cardiac markers in the ED. Studies on trop...

Use of cardiac markers in the ED. Studies on troponins in acute coronary syndrome.

Use of cardiac markers in the ED. Troponin I leve...
(Enlarge Image)
Media file 2: Use of cardiac markers in the ED. Troponin I levels and cardiac mortality in acute coronary syndrome.
[ CLOSE WINDOW ]
Use of cardiac markers in the ED. Troponin I leve...

Use of cardiac markers in the ED. Troponin I levels and cardiac mortality in acute coronary syndrome.

Use of cardiac markers in the ED. Cardiac event r...
(Enlarge Image)
Media file 3: Use of cardiac markers in the ED. Cardiac event rates in the platelet receptor inhibition for ischemic syndrome (PRISM) study based on troponin I results.
[ CLOSE WINDOW ]
Use of cardiac markers in the ED. Cardiac event r...

Use of cardiac markers in the ED. Cardiac event rates in the platelet receptor inhibition for ischemic syndrome (PRISM) study based on troponin I results.

Use of cardiac markers in the ED. Effect of time ...
(Enlarge Image)
Media file 4: Use of cardiac markers in the ED. Effect of time to treatment in patients with acute coronary syndrome (ACS) who are treated with the GIIb/IIIa inhibitor eptifibatide.
[ CLOSE WINDOW ]
Use of cardiac markers in the ED. Effect of time ...

Use of cardiac markers in the ED. Effect of time to treatment in patients with acute coronary syndrome (ACS) who are treated with the GIIb/IIIa inhibitor eptifibatide.

More on Use of Cardiac Markers in the Emergency Department

References
[ CLOSE WINDOW ]

References

  1. [Guideline] Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. Sep 2000;36(3):959-69. [Medline].

  2. [Guideline] Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. Aug 14 2007;50(7):e1-e157. [Medline].

  3. Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. Oct 31 1996;335(18):1342-9. [Medline].

  4. Heidenreich PA, Alloggiamento T, Melsop K, McDonald KM, Go AS, Hlatky MA. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis. J Am Coll Cardiol. Aug 2001;38(2):478-85. [Medline].

  5. Iliou MC, Fumeron C, Benoit MO, et al. Prognostic value of cardiac markers in ESRD: Chronic Hemodialysis and New Cardiac Markers Evaluation (CHANCE) study. Am J Kidney Dis. Sep 2003;42(3):513-23. [Medline].

  6. Ohman EM, Armstrong PW, Christenson RH, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med. Oct 31 1996;335(18):1333-41. [Medline].

  7. Stubbs P, Collinson P, Moseley D, Greenwood T, Noble M. Prognostic significance of admission troponin T concentrations in patients with myocardial infarction. Circulation. Sep 15 1996;94(6):1291-7. [Medline].

  8. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med. Oct 19 2000;343(16):1139-47. [Medline].

  9. Newby LK, Christenson RH, Ohman EM, et al. Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators. Circulation. Nov 3 1998;98(18):1853-9. [Medline].

  10. Lindahl B, Venge P, Wallentin L. Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. The FRISC study group. Circulation. May 1 1996;93(9):1651-7. [Medline].

  11. Apple FS, Parvin CA, Buechler KF, Christenson RH, Wu AH, Jaffe AS. Validation of the 99th percentile cutoff independent of assay imprecision (CV) for cardiac troponin monitoring for ruling out myocardial infarction. Clin Chem. Nov 2005;51(11):2198-200. [Medline].

  12. Eggers KM, Oldgren J, Nordenskjold A, Lindahl B. Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to troponin I for exclusion of myocardial infarction. Am Heart J. Oct 2004;148(4):574-81. [Medline].

  13. Macrae AR, Kavsak PA, Lustig V, et al. Assessing the requirement for the 6-hour interval between specimens in the American Heart Association Classification of Myocardial Infarction in Epidemiology and Clinical Research Studies. Clin Chem. May 2006;52(5):812-8. [Medline].

  14. Kavsak PA, MacRae AR, Newman AM, et al. Effects of contemporary troponin assay sensitivity on the utility of the early markers myoglobin and CKMB isoforms in evaluating patients with possible acute myocardial infarction. Clin Chim Acta. May 1 2007;380(1-2):213-6. [Medline].

  15. Saenger AK, Jaffe AS. Requiem for a heavyweight: the demise of creatine kinase-MB. Circulation. Nov 18 2008;118(21):2200-6. [Medline].

  16. Newby LK, Roe MT, Chen AY, et al. Frequency and clinical implications of discordant creatine kinase-MB and troponin measurements in acute coronary syndromes. J Am Coll Cardiol. Jan 17 2006;47(2):312-8. [Medline].

  17. Goodman SG, Steg PG, Eagle KA, et al. The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: lessons from the Global Registry of Acute Coronary Events (GRACE). Am Heart J. Mar 2006;151(3):654-60. [Medline].

  18. Adams JE 3rd, Bodor GS, Davila-Roman VG, et al. Cardiac troponin I. A marker with high specificity for cardiac injury. Circulation. Jul 1993;88(1):101-6. [Medline].

  19. Zimmerman J, Fromm R, Meyer D, et al. Diagnostic marker cooperative study for the diagnosis of myocardial infarction. Circulation. Apr 6 1999;99(13):1671-7. [Medline].

  20. Puleo PR, Meyer D, Wathen C, et al. Use of a rapid assay of subforms of creatine kinase-MB to diagnose or rule out acute myocardial infarction. N Engl J Med. Sep 1 1994;331(9):561-6. [Medline].

  21. Fesmire FM, Decker WW, Diercks DB, et al. Clinical policy: critical issues in the evaluation and management of adult patients with non-ST-segment elevation acute coronary syndromes. Ann Emerg Med. Sep 2006;48(3):270-301. [Medline].

  22. McCord J, Nowak RM, McCullough PA, et al. Ninety-minute exclusion of acute myocardial infarction by use of quantitative point-of-care testing of myoglobin and troponin I. Circulation. Sep 25 2001;104(13):1483-8. [Medline].

  23. [Guideline] Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation. Jan 15 2008;117(2):296-329. [Medline].

  24. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med. Aug 14 1997;337(7):447-52. [Medline].

  25. Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet. Mar 2 1996;347(9001):561-8. [Medline].

  26. PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med. May 21 1998;338(21):1488-97. [Medline].

  27. Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA. Sep 27 2000;284(12):1549-58. [Medline].

  28. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. Jun 21 2001;344(25):1879-87. [Medline].

  29. Morrow DA, Cannon CP, Rifai N, et al. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA. Nov 21 2001;286(19):2405-12. [Medline].

  30. Kleiman NS, Lakkis N, Cannon CP, et al. Prospective analysis of creatine kinase muscle-brain fraction and comparison with troponin T to predict cardiac risk and benefit of an invasive strategy in patients with non-ST-elevation acute coronary syndromes. J Am Coll Cardiol. Sep 18 2002;40(6):1044-50. [Medline].

  31. [Guideline] Nichols JH, Christenson RH, Clarke W, Gronowski A, Hammett-Stabler CA, Jacobs E, et al. Executive summary. The National Academy of Clinical Biochemistry Laboratory Medicine Practice Guideline: evidence-based practice for point-of-care testing. Clin Chim Acta. Apr 2007;379(1-2):14-28; discussion 29-30. [Medline].

  32. Newby LK, Storrow AB, Gibler WB, et al. Bedside multimarker testing for risk stratification in chest pain units: The chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study. Circulation. Apr 10 2001;103(14):1832-7. [Medline].

  33. Apple FS, Murakami MM, Christenson RH, et al. Analytical performance of the i-STAT cardiac troponin I assay. Clin Chim Acta. Jul 2004;345(1-2):123-7. [Medline].

  34. Ryan RJ, Lindsell CJ, Hollander JE, et al. A multicenter randomized controlled trial comparing central laboratory and point-of-care cardiac marker testing strategies: the Disposition Impacted by Serial Point of Care Markers in Acute Coronary Syndromes (DISPO-ACS) trial. Ann Emerg Med. Mar 2009;53(3):321-8. [Medline].

  35. Wu AH, Jaffe AS. The clinical need for high-sensitivity cardiac troponin assays for acute coronary syndromes and the role for serial testing. Am Heart J. Feb 2008;155(2):208-14. [Medline].

  36. James SK, Lindahl B, Armstrong P, et al. A rapid troponin I assay is not optimal for determination of troponin status and prediction of subsequent cardiac events at suspicion of unstable coronary syndromes. Int J Cardiol. Feb 2004;93(2-3):113-20. [Medline].

  37. Panteghini M, Pagani F, Yeo KT, et al. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin Chem. Feb 2004;50(2):327-32. [Medline].

  38. Aviles RJ, Askari AT, Lindahl B, et al. Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. N Engl J Med. Jun 27 2002;346(26):2047-52. [Medline].

  39. deFillippi C, Yoon A, Bounds C. Early detection of myocardial ischemia by a novel blood-based biomarker: the kinetics of ischemia modified albumin. JACC. 2003;41(6):Supplement 2:340A-341A.

  40. Stolear JC, Georges B, Shita A, Verbeelen D. The predictive value of cardiac troponin T measurements in subjects on regular haemodialysis. Nephrol Dial Transplant. Aug 1999;14(8):1961-7. [Medline].

  41. Ooi DS, Zimmerman D, Graham J, Wells GA. Cardiac troponin T predicts long-term outcomes in hemodialysis patients. Clin Chem. Mar 2001;47(3):412-7. [Medline].

  42. Freda BJ, Tang WH, Van Lente F, Peacock WF, Francis GS. Cardiac troponins in renal insufficiency: review and clinical implications. J Am Coll Cardiol. Dec 18 2002;40(12):2065-71. [Medline].

  43. Potluri S, Ventura HO, Mulumudi M, Mehra MR. Cardiac troponin levels in heart failure. Cardiol Rev. Jan-Feb 2004;12(1):21-5. [Medline].

  44. Sandhu R, Aronow WS, Rajdev A, et al. Relation of cardiac troponin I levels with in-hospital mortality in patients with ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage. Am J Cardiol. Sep 1 2008;102(5):632-4. [Medline].

  45. Morrow DA, de Lemos JA, Sabatine MS, et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol. Apr 16 2003;41(8):1264-72. [Medline].

  46. Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. Apr 16 2002;105(15):1760-3. [Medline].

  47. Sabatine MS, Morrow DA, de Lemos JA, et al. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol. Nov 16 2004;44(10):1988-95. [Medline].

  48. Zhang R, Brennan ML, Fu X, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. Nov 7 2001;286(17):2136-42. [Medline].

  49. Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. Oct 23 2003;349(17):1595-604. [Medline].

  50. Apple FS, Wu AH, Mair J, et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem. May 2005;51(5):810-24. [Medline].

  51. Apple FS, Smith SW, Pearce LA, Murakami MM. Assessment of the multiple-biomarker approach for diagnosis of myocardial infarction in patients presenting with symptoms suggestive of acute coronary syndrome. Clin Chem. Jan 2009;55(1):93-100. [Medline].

  52. Abadie JM, Blassingame CL, Bankson DD. Albumin cobalt binding assay to rule out acute coronary syndrome. Ann Clin Lab Sci. Winter 2005;35(1):66-72. [Medline].

  53. Peacock F, Morris DL, Anwaruddin S, et al. Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department. Am Heart J. Aug 2006;152(2):253-62. [Medline].

  54. Sinha MK, Roy D, Gaze DC, Collinson PO, Kaski JC. Role of "Ischemia modified albumin", a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes. Emerg Med J. Jan 2004;21(1):29-34. [Medline].

  55. Anwaruddin S, Januzzi JL Jr, Baggish AL, Lewandrowski EL, Lewandrowski KB. Ischemia-modified albumin improves the usefulness of standard cardiac biomarkers for the diagnosis of myocardial ischemia in the emergency department setting. Am J Clin Pathol. Jan 2005;123(1):140-5. [Medline].

  56. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med. May 21 1998;338(21):1498-505. [Medline].

  57. Abbate A, Biondi-Zoccai GG, Brugaletta S, Liuzzo G, Biasucci LM. C-reactive protein and other inflammatory biomarkers as predictors of outcome following acute coronary syndromes. Semin Vasc Med. Nov 2003;3(4):375-84. [Medline].

  58. Alexander JH, Sparapani RA, Mahaffey KW, et al. Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. JAMA. Jan 19 2000;283(3):347-53. [Medline].

  59. [Guideline] Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation. Aug 31 2004;110(9):e82-292. [Medline].

  60. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation. Oct 12 1999;100(15):1602-8. [Medline].

  61. Antman EM, Grudzien C, Mitchell RN, Sacks DB. Detection of unsuspected myocardial necrosis by rapid bedside assay for cardiac troponin T. Am Heart J. May 1997;133(5):596-8. [Medline].

  62. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation. Oct 12 1999;100(15):1593-601. [Medline].

  63. Apple FS, Christenson RH, Valdes R Jr, et al. Simultaneous rapid measurement of whole blood myoglobin, creatine kinase MB, and cardiac troponin I by the triage cardiac panel for detection of myocardial infarction. Clin Chem. Feb 1999;45(2):199-205. [Medline].

  64. Apple FS, Falahati A, Paulsen PR, Miller EA, Sharkey SW. Improved detection of minor ischemic myocardial injury with measurement of serum cardiac troponin I. Clin Chem. Nov 1997;43(11):2047-51. [Medline].

  65. Apple FS, Murakami MM. The diagnostic utility of cardiac biomarkers in detecting myocardial infarction. Clin Cornerstone. 2005;7 Suppl 1:S25-30. [Medline].

  66. Apple FS, Murakami MM, Christenson RH, et al. Analytical performance of the i-STAT cardiac troponin I assay. Clin Chim Acta. Jul 2004;345(1-2):123-7. [Medline].

  67. [Guideline] Apple FS, Quist HE, Doyle PJ, Otto AP, Murakami MM. Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations. Clin Chem. Aug 2003;49(8):1331-6. [Medline].

  68. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med. Oct 2002;252(4):283-94. [Medline].

  69. Brogan GX Jr, Friedman S, McCuskey C, et al. Evaluation of a new rapid quantitative immunoassay for serum myoglobin versus CK-MB for ruling out acute myocardial infarction in the emergency department. Ann Emerg Med. Oct 1994;24(4):665-71. [Medline].

  70. Choy JB, Armstrong PW, Ulan RA, et al. Do cardiac troponins provide prognostic insight in hemodialysis patients?. Can J Cardiol. Jul 2003;19(8):907-11. [Medline].

  71. Christenson RH, Duh SH, Newby LK, Ohman EM, Califf RM, Granger CB. Cardiac troponin T and cardiac troponin I: relative values in short-term risk stratification of patients with acute coronary syndromes. GUSTO-IIa Investigators. Clin Chem. Mar 1998;44(3):494-501. [Medline].

  72. Christenson RH, Duh SH, Sanhai WR, et al. Characteristics of an Albumin Cobalt Binding Test for assessment of acute coronary syndrome patients: a multicenter study. Clin Chem. Mar 2001;47(3):464-70. [Medline].

  73. Cohen M, Stinnett SS, Weatherley BD, et al. Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy. Am Heart J. Jun 2000;139(6):962-70. [Medline].

  74. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. Oct 4 2001;345(14):1014-21. [Medline].

  75. deFilippi C, Wasserman S, Rosanio S, et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA. Jul 16 2003;290(3):353-9. [Medline].

  76. deFilippi CR, Tocchi M, Parmar RJ, et al. Cardiac troponin T in chest pain unit patients without ischemic electrocardiographic changes: angiographic correlates and long-term clinical outcomes. J Am Coll Cardiol. Jun 2000;35(7):1827-34. [Medline].

  77. Dierkes J, Domrose U, Westphal S, et al. Cardiac troponin T predicts mortality in patients with end-stage renal disease. Circulation. Oct 17 2000;102(16):1964-9. [Medline].

  78. Fesmire FM. Delta CK-MB outperforms delta troponin I at 2 hours during the ED rule out of acute myocardial infarction. Am J Emerg Med. Jan 2000;18(1):1-8. [Medline].

  79. Fesmire FM, Christenson RH, Fody EP, Feintuch TA. Delta creatine kinase-MB outperforms myoglobin at two hours during the emergency department identification and exclusion of troponin positive non-ST-segment elevation acute coronary syndromes. Ann Emerg Med. Jul 2004;44(1):12-9. [Medline].

  80. Fesmire FM, Percy RF, Bardoner JB, Wharton DR, Calhoun FB. Serial creatinine kinase (CK) MB testing during the emergency department evaluation of chest pain: utility of a 2-hour deltaCK-MB of +1.6ng/ml. Am Heart J. Aug 1998;136(2):237-44. [Medline].

  81. Fleming SM, Daly KM. Cardiac troponins in suspected acute coronary syndrome: a meta-analysis of published trials. Cardiology. 2001;95(2):66-73. [Medline].

  82. Gibler WB, Young GP, Hedges JR, et al. Acute myocardial infarction in chest pain patients with nondiagnostic ECGs: serial CK-MB sampling in the emergency department. The Emergency Medicine Cardiac Research Group. Ann Emerg Med. May 1992;21(5):504-12. [Medline].

  83. GUSTO IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Circulation. Oct 1994;90(4):1631-7. [Medline].

  84. Hamm CW, Goldmann BU, Heeschen C, Kreymann G, Berger J, Meinertz T. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl J Med. Dec 4 1997;337(23):1648-53. [Medline].

  85. Hoekstra JW, Hedges JR, Gibler WB, Rubison RM, Christensen RA. Emergency department CK-MB: a predictor of ischemic complications. National cooperative CK-MB project group. Acad Emerg Med. Jan-Feb 1994;1(1):17-27. [Medline].

  86. Hutter AM Jr, Amsterdam EA, Jaffe AS. 31st Bethesda Conference. Emergency Cardiac Care. Task force 2: Acute coronary syndromes: Section 2B--Chest discomfort evaluation in the hospital. J Am Coll Cardiol. Mar 15 2000;35(4):853-62. [Medline].

  87. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med. Aug 13 1998;339(7):436-43. [Medline].

  88. James SK, Armstrong P, Barnathan E, et al. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. J Am Coll Cardiol. Mar 19 2003;41(6):916-24. [Medline].

  89. Karlson BW, Herlitz J, Wiklund O, Richter A, Hjalmarson A. Early prediction of acute myocardial infarction from clinical history, examination and electrocardiogram in the emergency room. Am J Cardiol. Jul 15 1991;68(2):171-5. [Medline].

  90. Koenig W. Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein. Int J Cardiol. Feb 15 2005;98(2):199-206. [Medline].

  91. Kontos MC, Anderson FP, Hanbury CM, Roberts CS, Miller WG, Jesse RL. Use of the combination of myoglobin and CK-MB mass for the rapid diagnosis of acute myocardial infarction. Am J Emerg Med. Jan 1997;15(1):14-9. [Medline].

  92. Kontos MC, Schorer S, Kirk JD. Ischemia modified albumin: a new biomarker of myocardial ischemia for early diagnosis of acute coronary syndromes. JACC. 2003;41(6):Supplement 2:340A.

  93. Kontos MC, Shah R, Fritz LM, et al. Implication of different cardiac troponin I levels for clinical outcomes and prognosis of acute chest pain patients. J Am Coll Cardiol. Mar 17 2004;43(6):958-65. [Medline].

  94. Maisel A, Mehra MR. Understanding B-type natriuretic peptide and its role in diagnosing and monitoring congestive heart failure. Clin Cornerstone. 2005;7 Suppl 1:S7-17. [Medline].

  95. Manolio T. Novel risk markers and clinical practice. N Engl J Med. Oct 23 2003;349(17):1587-9. [Medline].

  96. Newby LK, Kaplan AL, Granger BB, Sedor F, Califf RM, Ohman EM. Comparison of cardiac troponin T versus creatine kinase-MB for risk stratification in a chest pain evaluation unit. Am J Cardiol. Apr 1 2000;85(7):801-5. [Medline].

  97. Ohman EM, Armstrong PW, White HD, et al. Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies To Open Occluded Coronary Arteries. Am J Cardiol. Dec 1 1999;84(11):1281-6. [Medline].

  98. Olatidoye AG, Wu AH, Feng YJ, Waters D. Prognostic role of troponin T versus troponin I in unstable angina pectoris for cardiac events with meta-analysis comparing published studies. Am J Cardiol. Jun 15 1998;81(12):1405-10. [Medline].

  99. Peetz D, Schutt S, Sucke B, et al. Prognostic value of troponin T, troponin I, and CK-MBmass in patients with chronic renal failure. Med Klin (Munich). Apr 15 2003;98(4):188-92. [Medline].

  100. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet. May 17 1997;349(9063):1429-35. [Medline].

  101. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. Sep 1 1998;98(9):839-44. [Medline].

  102. Roxin LE, Cullhed I, Groth T, Hallgren T, Venge P. The value of serum myoglobin determinations in the early diagnosis of acute myocardial infarction. Acta Med Scand. 1984;215(5):417-25. [Medline].

  103. Sabatine MS, Morrow DA, de Lemos JA, et al. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol. Nov 16 2004;44(10):1988-95. [Medline].

  104. Sadanandan S, Cannon CP, Chekuri K, et al. Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol. Aug 4 2004;44(3):564-8. [Medline].

  105. Savonitto S, Granger CB, Ardissino D, et al. The prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary syndromes. J Am Coll Cardiol. Jan 2 2002;39(1):22-9. [Medline].

  106. Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet. Jun 16 2001;357(9272):1915-24. [Medline].

  107. Sinha MK, Gaze DC, Tippins JR, Collinson PO, Kaski JC. Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention. Circulation. May 20 2003;107(19):2403-5. [Medline].

  108. The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. Circulation. Apr 1994;89(4):1545-56. [Medline].

  109. [Guideline] Wu AH, Apple FS, Gibler WB, Jesse RL, Warshaw MM, Valdes R Jr. National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases. Clin Chem. Jul 1999;45(7):1104-21. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

cardiac markers, chest pain, acute coronary syndrome, ACS, acute myocardial infarction, AMI, myocardial infarction, MI, troponin, myoglobin, cardiac troponin, creatine kinase–MB, CK-MB, biochemical marker, non–ST-segment elevation MI, NSTEMI, ST-segment elevation, STEMI

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Donald Schreiber, MD, CM, Associate Professor of Surgery (Emergency Medicine), Stanford University School of Medicine
Donald Schreiber, MD, CM is a member of the following medical societies: American College of Emergency Physicians
Disclosure: Abbott Point of Care Inc Research Grant and Speaker''''''''''''''''s Bureau Speaking and teaching; Bristol-Myers Squibb Inc Honoraria Speaking and teaching; Sanofi-Aventis, Inc Honoraria Speaking and teaching; Nanosphere Inc Grant/research funds Research; Singulex Inc Grant/research funds Research

Coauthor(s)

Suzanne M Miller, MD, Clinical Instructor, Emergency Medicine, George Washington University School of Medicine and Health Sciences; Attending Physician, Department of Emergency Medicine, INOVA Fairfax Hospital; Chief Executive Officer, MDadmit
Suzanne M Miller, MD is a member of the following medical societies: American Academy of Emergency Medicine and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Medical Editor

Edward Bessman, MD, Chairman, Department of Emergency Medicine, John Hopkins Bayview Medical Center; Assistant Professor, Department of Emergency Medicine, Johns Hopkins University
Edward Bessman, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Gary Setnik, MD, Chair, Department of Emergency Medicine, Mount Auburn Hospital; Assistant Professor, Division of Emergency Medicine, Harvard Medical School
Gary Setnik, MD is a member of the following medical societies: American College of Emergency Physicians, National Association of EMS Physicians, and Society for Academic Emergency Medicine
Disclosure: SironaHealth Salary Management position; South Middlesex EMS Consortium Salary Management position

CME Editor

John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center
John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Chief Editor

David FM Brown, MD, Assistant Professor, Division of Emergency Medicine, Harvard Medical School; Vice Chair, Department of Emergency Medicine, Massachusetts General Hospital
David FM Brown, MD is a member of the following medical societies: American College of Emergency Physicians and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.